Risk of IFIS with Risperdal®, Risperdal® Consta®, Risperdal® Quicklet®, Invega® and Invega® Sustenna®

Janssen would like to inform healthcare professionals of the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients treated with RISPERDAL® (risperidone) and INVEGA® (paliperidone) range of products. Cases of IFIS associated with the use of antipsychotic agents that have alpha-adrenergic receptor blocking activity, including risperidone, have been reported in the literature. During routine pharmacovigilance surveillance by the Company, an increase in the reporting frequency of IFIS with the use of RISPERDAL® was detected. The frequency of reports on IFIS and risperidone is estimated as very rare. Healthcare professionals are advised to ask patients about current or prior use of RISPERDAL® and INVEGA® products when taking medication history preoperatively. If IFIS is suspected, modifications to surgical technique may be required and cataract surgeons need to approach the surgery with caution. This new safety information is updated in the packet inserts of all RISPERDAL® and INVEGA® products. Please refer to the letter for further information. 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

24 Feb 2021

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.